Price$1.49-0.05 (-3.57%)
01:30 PM07:45 PM
News · 26 weeks37+25%
2026-01-252026-07-19
Mix2990d
- Market16(55%)
- SEC Filings11(38%)
- Other2(7%)
Latest news
25 items- NEWSNanoViricides Announces Pricing of ~$3.8 Million Registered Direct OfferingSHELTON, CT / ACCESS Newswire / July 24, 2026 / NanoViricides, Inc. (NYSE:NNVC) ("NanoViricides" or the "Company"), a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses and their variants cannot escape, today announced it has entered into a securities purchase agreement with a single fundamental institutional investor for the purchase and sale of 2,516,339 shares of common stock (or pre-funded warrants in lieu thereof), together with accompanying warrants to purchase 2,516,339 shares of common stock for gross proceeds of approximately US$3.8 million in a registered direct offering (the "Offering").
- NEWSAs Ebola Death Toll Surpasses 930 Within Two Months, NanoViricides Has Applied to the DR Congo Regulatory Agency for Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for EbolaSHELTON, CT / ACCESS Newswire / July 22, 2026 / NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that it has applied to the regulatory agency, ACOREP, for approval to begin a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for the Current Bundibugyo Ebolavirus in the Democratic Republic of Congo (DRC).NanoViricides has retained Om Sai Clinical Research Private Limited, India, as the CRO for this Phase II clinical trial for Ebola in DRC. Om Sai CRO has been instrumental in putting together a team with a renowned Principal Investigator and other renowned experts and with support from a well k
- SECNanoViricides Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - NANOVIRICIDES, INC. (0001379006) (Filer)
- SECSEC Form 424B5 filed by NanoViricides Inc.424B5 - NANOVIRICIDES, INC. (0001379006) (Filer)
- NEWSAs Ebola Spreads in Two More Provinces, NanoViricides Has Received National Ethics Committee Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in CongoSHELTON, CT / ACCESS Newswire / July 13, 2026 / NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that it has received National Ethics Committee approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for the Current Bundibugyo Ebolavirus in the Democratic Republic of Congo (DRC). The Company is now getting ready to file a Clinical Trial Application to ACOREP, the regulatory agency in DRC.NanoViricides has already put together a team with a renowned Principal Investigator and with support from a well known University in the Ebola-affected region for the execution of this clinical tria
- NEWSResearch Analyst Report on NanoViricides Rates Company "Outperform"; Separately, A "Fireside Chat" Interview of the Company's President Dr. Anil Diwan Hosted by Mr. Dave Donlin was Published by StockInvestor DailySHELTON, CT / ACCESS Newswire / July 8, 2026 / NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, reports that a Coverage Initiating Research Report on the Company by an Independent Analyst has been published, dated as of July 6, 2026.The report rates the Company with a rating of "Outperform" and has assigned a target price of $6.00, based on the analyst's estimates. This research report provides a summary of the Company's current programs, as well as additional longer term programs. The report was written by Mr. Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, In
- NEWSAs the Ebola Epidemic Spreads, NanoViricides Advances Towards a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR CongoSHELTON, CT / ACCESS Newswire / July 6, 2026 / NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, updates that it has continued to advance its broad-spectrum antiviral drug NV-387 towards a Phase II Clinical Trial of the NV-387 Oral Gummies formulation as a Treatment for the Current Bundibugyo Ebolavirus in the Democratic Republic of Congo (DRC).NanoViricides has already put together a team with a renowned Principal Investigator and with support from a well known University in the Ebola-affected region for the execution of this clinical trial after regulatory approvals.NanoViricides' proposal for the said clinical t
- SECSEC Form 424B3 filed by NanoViricides Inc.424B3 - NANOVIRICIDES, INC. (0001379006) (Filer)
- NEWSUS FDA Has Granted A "Rare Pediatric Disease Drug" Designation for NV-387 As A Treatment for Measles - Enables Priority Review VoucherSHELTON, CT / ACCESS Newswire / June 29, 2026 / NanoViricides, Inc., a publicly traded company (NYSE:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, announced today that its clinical stage, broad-spectrum, antiviral drug NV-387 has been granted a "Rare Pediatric Disease Drug" (RPDD) Designation by the US FDA Office of Orphan Products Development (OOPD).This RPDD designation enables that a Priority Review Voucher (PRV) can be issued to the Company upon a successful Marketing Application (i.e. New Drug Application) for the use of NV-387 as a treatment fo
- SECSEC Form EFFECT filed by NanoViricides Inc.EFFECT - NANOVIRICIDES, INC. (0001379006) (Filer)
- SECSEC Form DEL AM filed by NanoViricides Inc.DEL AM - NANOVIRICIDES, INC. (0001379006) (Filer)
- NEWSNanoViricides Has Shipped NV-387 Oral Gummies Drug Product for Phase II Clinical Trial to DR CongoSHELTON, CT / ACCESS Newswire / June 22, 2026 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company") today announced that it has shipped the NV-387 Oral Gummies Drug Product for a Phase II Clinical Trial of Monkeypox Treatment to the Democratic Republic of Congo (DRC), in preparation for enrollment of patients.Clinical Trial Site preparations are being performed by our CRO in India, Om Sai Clinical Research Pvt. Ltd., and associates in DRC. The CRO personnel have visited the site several times, despite travel restrictions, and changing flight schedules and cancellations, as required for the preparations. Enrollment and dosing of patients is expected to begin after the staff training is comp
- SECSEC Form DEL AM filed by NanoViricides Inc.DEL AM - NANOVIRICIDES, INC. (0001379006) (Filer)
- SECSEC Form EFFECT filed by NanoViricides Inc.EFFECT - NANOVIRICIDES, INC. (0001379006) (Filer)
- SECSEC Form S-3 filed by NanoViricides Inc.S-3 - NANOVIRICIDES, INC. (0001379006) (Filer)
- NEWSAs the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment of Ebola - NanoViricides Proposal is Approved by the Pillar Committee in DR CongoSHELTON, CT / ACCESS Newswire / June 15, 2026 / NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, NanoViricides announces that its proposal to perform a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for the Current Bundibugyo Ebolavirus has been approved by the Pillar Committee in Charge in the Democratic Republic of Congo (DRC).There is no approved treatment or vaccine for the new variant of the Bundibugyo Ebolavirus (BDBV) that is causing the current rapidly expanding outbreak of the Ebolavirus Disease (EVD) in DR Congo and Uganda. The rare Bundibugyo strain of Ebola virus causing the current outb
- NEWSAs the Ebola Emergency Outbreak Grows Rapidly, NanoViricides Has Proposed a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment - with Superior Oral Administration and Escape Resistance Features Over AntibodiesSHELTON, CT / ACCESS Newswire / June 8, 2026 / NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, NanoViricides announces that it has proposed a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for the Current Bundibugyo Ebolavirus to the Committee in Charge in the Democratic Republic of Congo (DRC).The rare Bundibugyo strain of Ebola virus causing the current outbreak appears to be its new variant, likely freshly introduced from some animal source[1], such as fruit bats.The outbreak which was declared a Public Health Emergency of International Concern ("PHEIC") by the WHO on May 17, 2026, continues to
- SECSEC Form S-3 filed by NanoViricides Inc.S-3 - NANOVIRICIDES, INC. (0001379006) (Filer)
- NEWSIn the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricidesSHELTON, CT / ACCESS Newswire / May 26, 2026 / NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, compares potential treatment options for Ebola Bundibugyo virus strain and finds that the Company's broad-spectrum antiviral drug candidate NV-387 is worthy of evaluation in this scenario.The rare Bundibugyo strain of Ebola virus causing the current outbreak appears to be its new variant, likely freshly introduced from some animal source[1], such as fruit bats.The outbreak which was declared a public health emergency of international concern by the WHO on May 16, 2026, is rapidly expanding, outpacing containment efforts
- SECNanoViricides Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - NANOVIRICIDES, INC. (0001379006) (Filer)
- SECNanoViricides Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits8-K - NANOVIRICIDES, INC. (0001379006) (Filer)
- NEWSNanoViricides Announces Closing of ~$2 Million Registered Direct OfferingSHELTON, CT / ACCESS Newswire / May 18, 2026 / NanoViricides, Inc. (NYSE:NNVC) ("NanoViricides" or the "Company"), a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses and their variants cannot escape, today announced the closing of its previously announced registered direct offering (the "Offering") of 1,333,334 million shares of common stock (or pre-funded warrants in lieu thereof), together with accompanying warrants to purchase 1,333,334 common shares (the "Offering"). The Offering was made to a single, fundamental institutional investor and priced at-the-market price of US$1.50 for each common
- SECSEC Form 424B5 filed by NanoViricides Inc.424B5 - NANOVIRICIDES, INC. (0001379006) (Filer)
- NEWSEbola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricidesSHELTON, CT / ACCESS Newswire / May 18, 2026 / NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, emphasizes the critical need for a revolutionary, broad-spectrum, antiviral drug like NV-387 as another severe Ebolavirus outbreak has occurred in the Eastern part of DR Congo (DRC), with spillage across the border into Uganda."We believe NV-387 could be effective against the Bundibugyo strain of Ebola that is ravaging DRC," said Anil R. Diwan, PhD, adding, "All filoviruses including all Ebola strains utilize the sulfated proteoglycans for initial cell attachment; which is the feature that NV-387 presents to the viruses
- NEWSNanoViricides Announces Pricing of ~$2 Million Registered Direct OfferingSHELTON, CT / ACCESS Newswire / May 15, 2026 / NanoViricides, Inc. (NYSE:NNVC) ("NanoViricides" or the "Company"), a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses and their variants cannot escape, today announced it has entered into a securities purchase agreement with a single fundamental institutional investor for the purchase and sale of 1,333,334 million common shares (or pre-funded warrants in lieu thereof), together with accompanying warrants to purchase 1,333,334 common shares for gross proceeds of approximately US$2 million in a registered direct offering (the "Offering"). The common s
NNVC FAQ
6 questionsWhat does NanoViricides Inc. do?
NanoViricides, Inc., a nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. Its products pipeline includes HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis. The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases...Where does NNVC stock trade?
NanoViricides Inc. (NNVC) is listed on AMEX.What sector and industry is NNVC in?
NanoViricides Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about NNVC?
NanoViricides Inc. has had 1 recent analyst action on file. The most recent action was from Alliance Global Partners: Buy on 2025-12-16.What companies are similar to NNVC?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare NNVC side-by-side with any of them on Quantisnow.How can I track NNVC on Quantisnow?
Quantisnow aggregates NanoViricides Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NNVC to receive live email and push alerts on every new disclosure.